Pharmacokinetic Interactions of Drugs with St John’s Wort
Open accessThe DOI matches its Crossref record; 137 of the 137 references it cites were found in a registry or an index.
Abstract
There is a worldwide increasing use of herbs which are often administered in combination with therapeutic drugs, raising the potential for herb-drug interactions. St John’s wort ( Hypericum perforatum) is one of the most commonly used herbal antidepressants. A literature search was performed using Medline (via Pubmed), Biological Abstracts, Cochrane Library, AMED, PsycINFO and Embase (all from their inception to September 2003) to identify known drug interaction with St John’s wort. The available data indicate that St John’s wort is a potent inducer of CYP 3A4 and P-glycoprotein (PgP), although it may inhibit or induce other CYPs, depending on the dose, route and duration of administration. Data from human studies and case reports indicate that St John’s wort decreased the blood concentrations of amitriptyline, cyclosporine, digoxin, fexofenadine, indinavir, methadone, midazolam, nevirapine, phenprocoumon, simvastatin, tacrolimus, theophylline and warfarin, whereas it did not alter the pharmacokinetics of carbamazepine, dextromethorphan, mycophenolic acid and pravastatin. St John’s wort decreased the plasma concentration of the active metabolite SN-38 in cancer patients receiving irinotecan treatment. St John’s wort did not alter the pharmacokinetics of tolbutamide, but increased the incidence of hypoglycaemia. Several cases have been reported that St John’s wort decreased cyclosporine blood concentration leading to organ rejection. St John’s wort caused breakthrough bleeding and unplanned pregnancies when used concomitantly with oral contraceptives. It also caused serotonin syndrome when coadministered with selective serotonin-reuptake inhibitors (e.g. sertaline and paroxetine). Both pharmacokinetic and pharmacodynamic components may play a role in these interactions. Because the potential interaction of St John’s wort with other drugs is a major safety concern, additional systematic research on herb-drug interactions and appropriate regulation in herbal safety and efficacy is needed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
BIOCHEMISTRY OF MULTIDRUG RESISTANCE MEDIATED BY THE MULTIDRUG TRANSPORTER
Gottesman, M. M., & Pastan, I. (1993) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.62.070193.002125 · Cited by 3,568
P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature
Nelson, D. R., Koymans, L., Kamataki, T., Stegeman, J. J., Feyereisen, R., Waxman, D. J., Waterman, M. R., Gotoh, O., Coon, M. J., Estabrook, R. W., et al. (1996) · Pharmacogenetics · doi:10.1097/00008571-199602000-00002 · Cited by 2,945
Shimada, T., Yamazaki, H., Mimura, M., Inui, Y., & Guengerich, F. P. (1994) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)22379-5 · Cited by 2,785 · cited 2×
“The relative abundance of the hepatic CYPs in humans has been determined as: CYP1A2 (13%), 2A6 (4%), 2B6 (< 1%), 2C (20%), 2D6 (2%), 2E1 (7%) and 3A4 (30%) (Shimada et al., 1994; Rendic and Di Carlo, 1997).”
BIOCHEMICAL, CELLULAR, AND PHARMACOLOGICAL ASPECTS OF THE MULTIDRUG TRANSPORTER
Ambudkar, S. V., Dey, S., Hrycyna, C. A., Ramachandra, M., Pastan, I., & Gottesman, M. M. (1999) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.39.1.361 · Cited by 2,059
Chen, C.-J., Chin, J. E., Ueda, K., Clark, D. P., Pastan, I., Gottesman, M. M., & Roninson, I. B. (1986) · Cell · doi:10.1016/0092-8674(86)90595-7 · Cited by 1,898
An Orphan Nuclear Receptor Activated by Pregnanes Defines a Novel Steroid Signaling Pathway
Kliewer, S. A., Moore, J. T., Wade, L., Staudinger, J. L., Watson, M. A., Jones, S. A., McKee, D. D., Oliver, B. B., Willson, T. M., Zetterström, R. H., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)80900-9 · Cited by 1,539
Clinical importance of the cytochromes P450
Nebert, D. W., & Russell, D. W. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11203-7 · Cited by 1,414
Schinkel, A. H., Wagenaar, E., van Deemter, L., Mol, C. A., & Borst, P. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118214 · Cited by 1,107
Fugh-Berman, A. (2000) · The Lancet · doi:10.1016/s0140-6736(99)06457-0 · Cited by 1,099
Role of P-Glycoprotein in Pharmacokinetics: Clinical Implications
Lin, J. H., & Yamazaki, M. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342010-00003 · Cited by 998
Rendic, S., & Carlo, F. J. D. (1997) · Drug Metabolism Reviews · doi:10.3109/03602539709037591 · Cited by 949
St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor
Moore, L. B., Goodwin, B., Jones, S. A., Wisely, G. B., Serabjit-Singh, C. J., Willson, T. M., Collins, J. L., & Kliewer, S. A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.130155097 · Cited by 947
The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin
Greiner, B., Eichelbaum, M., Fritz, P., Kreichgauer, H.-P., von Richter, O., Zundler, J., & Kroemer, H. K. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6663 · Cited by 917
(2006) · Pharmacodynamic Basis of Herbal Medicine, Second Edition · doi:10.1201/9781420006452.ch4 · Cited by 905
Indinavir concentrations and St John's wort
Piscitelli, S. C., Burstein, A. H., Chaitt, D., Alfaro, R. M., & Falloon, J. (2000) · The Lancet · doi:10.1016/s0140-6736(99)05712-8 · Cited by 874
Nuclear Receptor Response Elements Mediate Induction of Intestinal MDR1 by Rifampin
Geick, A., Eichelbaum, M., & Burk, O. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010173200 · Cited by 848
IN VITRO AND IN VIVO DRUG INTERACTIONS INVOLVING HUMAN CYP3A
Thummel, K. E., & Wilkinson, G. R. (1998) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.38.1.389 · Cited by 831
Summary of information on human CYP enzymes: human P450 metabolism data
Rendic, S. (2002) · Drug Metabolism Reviews · doi:10.1081/dmr-120001392 · Cited by 820
Human P450 metabolism of warfarin
Kaminsky, L. S., & Zhang, Z.-Y. (1997) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(96)00140-4 · Cited by 798
CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants
Bradford, L. D. (2002) · Pharmacogenomics · doi:10.1517/14622416.3.2.229 · Cited by 773
Bertz, R. J., & Granneman, G. R. (1997) · Clinical Pharmacokinetics · doi:10.2165/00003088-199732030-00004 · Cited by 755
Interactions Between Herbal Medicines and Prescribed Drugs: A Systematic Review
Izzo, A. A., & Ernst, E. (2001) · Drugs · doi:10.2165/00003495-200161150-00002 · Cited by 714
Lown, K. S., Mayo, R. R., Leichtman, A. B., Hsiao, H.-L., Turgeon, D. K., Schmiedlin-Ren, P., Brown, M. B., Guo, W., Rossi, S. J., Benet, L. Z., et al. (1997) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(97)90027-8 · Cited by 680
Mechanism of the Cardiotoxic Actions of Terfenadine
Woosley, R. L. (1993) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1993.03500120070028 · Cited by 646 · cited 1×
“Fexofenadine is the active metabolite of the terfenadine, but has an advantage over the latter that it is not cardiotoxic and does not cause the rare but potentially fatal adverse reaction associated with certain drug interactions involving the latter (Woosley et al., 1993).”
BackgroundAcute heart transplant rejection due to Saint John's wort
Ruschitzka, F., Meier, P. J., Turina, M., Lüscher, T. F., & Noll, G. (2000) · The Lancet · doi:10.1016/s0140-6736(99)05467-7 · Cited by 644
Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review
Vaswani, M., Linda, F. K., & Ramesh, S. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(02)00338-x · Cited by 612
OATP and P-Glycoprotein Transporters Mediate the Cellular Uptake and Excretion of Fexofenadine
Cvetkovic, M., Leake, B., Fromm, M. F., Wilkinson, G. R., & Kim, R. B. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15235-x · Cited by 597
JOHNE, A. (1999) · Clinical Pharmacology & Therapeutics · doi:10.1053/cp.1999.v66.a101944 · Cited by 586
St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4
Dürr, D. (2000) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2000.112240 · Cited by 584
Kronbach, T., Fischer, V., & Meyer, U. A. (1988) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1988.87 · Cited by 533
Evolution of the P450 gene superfamily:
Gonzalez, F. J., & Nebert, D. W. (1990) · Trends in Genetics · doi:10.1016/0168-9525(90)90174-5 · Cited by 514
Ito, K., Iwatsubo, T., Kanamitsu, S., Ueda, K., Suzuki, H., & Sugiyama, Y. (1998) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01372-3 · Cited by 512
Effects of St. John's wort on irinotecan metabolism.
Mathijssen, R. H. J. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.16.1247 · Cited by 457
Human liver carbamazepine metabolism
Kerr, B. M., Thummel, K. E., Wurden, C. J., Klein, S. M., Kroetz, D. L., Gonzalez, F. J., & Levy, R. (1994) · Biochemical Pharmacology · doi:10.1016/0006-2952(94)90071-x · Cited by 433
Interactions of Herbs with Cytochrome P450
Zhou, S., Gao, Y., Jiang, W., Huang, M., Xu, A., & Paxton, J. W. (2003) · Drug Metabolism Reviews · doi:10.1081/dmr-120018248 · Cited by 397
Self-citationObach, R. S. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)39043-3 · Cited by 397
Christopher Gorski, J., Hall, S. D., Jones, D. R., & VandenBranden, M. (1994) · Biochemical Pharmacology · doi:10.1016/0006-2952(94)90543-6 · Cited by 395
Effect of grapefruit juice on digoxin pharmacokinetics in humans
Becquemont, L., Verstuyft, C., Kerb, R., Brinkmann, U., Lebot, M., Jaillon, P., & Funck‐Brentano, C. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(01)17221-8 · Cited by 387
Sattler, M., Guengerich, F. P., Yun, C. H., Christians, U., & Sewing, K. F. (1992) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)08793-8 · Cited by 385
Conseil, G., Baubichon-Cortay, H., Dayan, G., Jault, J.-M., Barron, D., & Di Pietro, A. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.17.9831 · Cited by 381
Regulation of the Human CYP2B6 Gene by the Nuclear Pregnane X Receptor
Goodwin, B., Moore, L. B., Stoltz, C. M., McKee, D. D., & Kliewer, S. A. (2001) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)12603-x · Cited by 374
Herb–drug interactions: Review and assessment of report reliability
Fugh‐Berman, A., & Ernst, E. (2001) · British Journal of Clinical Pharmacology · doi:10.1046/j.0306-5251.2001.01469.x · Cited by 364
Cytochrome P450 phenotypic ratios for predicting herb‐drug interactions in humans
Gurley, B. J., Gardner, S. F., Hubbard, M. A., Williams, D. K., Gentry, W. B., Cui, Y., & Ang, C. Y. W. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.126913 · Cited by 343
Regulation of CYP3A Gene Transcription by the Pregnane X Receptor
Goodwin, B., Redinbo, M. R., & Kliewer, S. A. (2002) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.42.111901.111051 · Cited by 327
St John's Wort: Effect on CYP3A4 activity
Roby, C. (2000) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2000.106793 · Cited by 316
Combalbert, J., Fabre, I., Fabre, G., Dalet, I., Derancourt, J., Cano, J. P., & Maurel, P. (1989) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)08744-6 · Cited by 306
Second thoughts about safety of St John's wort
Ernst, E. (1999) · The Lancet · doi:10.1016/s0140-6736(99)00418-3 · Cited by 305
St John's Wort increases expression of P‐glycoprotein: Implications for drug interactions
Hennessy, M., Kelleher, D., Spiers, J. P., Barry, M., Kavanagh, P., Back, D., Mulcahy, F., & Feely, J. (2002) · British Journal of Clinical Pharmacology · doi:10.1046/j.0306-5251.2001.01516.x · Cited by 280
St John's wort: Prozac from the plant kingdom
Di Carlo, G., Borrelli, F., Ernst, E., & Izzo, A. A. (2001) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(00)01716-8 · Cited by 277
Erickson, D. A., Mather, G., Trager, W. F., Levy, R. H., & Keirns, J. J. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)14960-4 · Cited by 277
Lampen, A., Christians, U., Guengerich, F. P., Watkins, P. B., Kolars, J. C., Bader, A., Gonschior, A. K., Dralle, H., Hackbarth, I., & Sewing, K. F. (1995) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)06862-x · Cited by 273
(1997) · PubMed · Cited by 271
Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects
Dresser, G. K., Schwarz, U. I., Wilkinson, G. R., & Kim, R. B. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2003.10 · Cited by 261
Irinotecan (CPT-11) High-Dose Escalation Using Intensive High-Dose Loperamide to Control Diarrhea
Abigerges, D., Armand, J.-P., Chabot, G. G., Costa, L. D., Fadel, E., Cote, C., Herait, P., & Gandia, D. (1994) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/86.6.446 · Cited by 248
Different effects of St John's Wort on the pharmacokinetics of simvastatin and pravastatin
Sugimoto, K., Ohmori, M., Tsuruoka, S., Nishiki, K., Kawaguchi, A., Harada, K., Arakawa, M., Sakamoto, K., Masada, M., Miyamori, I., et al. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(01)64092-x · Cited by 247
Metabolic disposition studies on simvastatin, a cholesterol-lowering prodrug.
Vickers, S., Duncan, C. A., Chen, I. W., Rosegay, A., & Duggan, D. E. (1990) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)07595-6 · Cited by 246
Pharmacokinetic interactions between herbal remedies and medicinal drugs
Ioannides, C. (2002) · Xenobiotica · doi:10.1080/00498250210124147 · Cited by 237
St John's wort, a herbal antidepressant, activates the steroid X receptor
Wentworth, J., Agostini, M., Love, J., Schwabe, J., & Chatterjee, V. (2000) · Journal of Endocrinology · doi:10.1677/joe.0.166r011 · Cited by 236
Effect of grapefruit juice on digoxin pharmacokinetics in humans.
Becquemont, L., Verstuyft, C., Kerb, R., Brinkmann, U., Lebot, M., Jaillon, P., & Funck‐Brentano, C. (2001) · PubMed · Cited by 234
von Moltke, L. L., Greenblatt, D. J., Harmatz, J. S., Duan, S. X., Harrel, L. M., Cotreau-Bibbo, M. M., Pritchard, G. A., Wright, C. E., & Shader, R. I. (1996) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)12284-2 · Cited by 225
Fitzsimmons, M. E., & Collins, J. M. (1997) · PubMed · Cited by 221
Drug Interaction between St. John's Wort and Cyclosporine
Barone, G. W., Gurley, B. J., Ketel, B. L., Lightfoot, M. L., & Abul-Ezz, S. R. (2000) · Annals of Pharmacotherapy · doi:10.1345/aph.10088 · Cited by 216
Effect of St John's wort on the pharmacokinetics of fexofenadine
Wang, Z., Hamman, M. A., Huang, S., Lesko, L. J., & Hall, S. D. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.124080 · Cited by 213
Oral Bioavailability of Hyperforin from Hypericum Extracts in Rats and Human Volunteers
Biber, A., Fischer, H., Römer, A., & Chatterjee, S. (1998) · Pharmacopsychiatry · doi:10.1055/s-2007-979344 · Cited by 212
Influence of Diet and Nutritional Status on Drug Metabolism
Walter-Sack, I., & Klotz, U. (1996) · Clinical Pharmacokinetics · doi:10.2165/00003088-199631010-00004 · Cited by 209
St. John's Wort and Antidepressant Drug Interactions in the Elderly
Lantz, M. S., Buchalter, E., & Giambanco, V. (1999) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/089198879901200103 · Cited by 208
Potential Metabolic Interaction between St. John's Wort and Theophylline
(1999) · Annals of Pharmacotherapy · doi:10.1345/aph.18252 · Cited by 201
The Contribution of P‐glycoprotein to Pharmacokinetic Drug‐Drug Interactions
Yu, D. K. (1999) · The Journal of Clinical Pharmacology · doi:10.1177/00912709922012006 · Cited by 199
Methadone Use in Cancer Patients with Pain: A Review
Bruera, E., & Sweeney, C. (2002) · Journal of Palliative Medicine · doi:10.1089/10966210252785097 · Cited by 197
HMG‐CoA reductase inhibitors and P‐glycoprotein modulation
Bogman, K., Peyer, A., Török, M., Küsters, E., & Drewe, J. (2001) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0703920 · Cited by 194
Bauer, S., Störmer, E., Johne, A., Krüger, H., Budde, K., Neumayer, H., Roots, I., & Mai, I. (2003) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.01759.x · Cited by 188
Gupta, E., Mick, R., Ramirez, J., Wang, X., Lestingi, T. M., Vokes, E. E., & Ratain, M. J. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.4.1502 · Cited by 182
Drug interaction between St John's wort and nevirapine
de Maat, M. M. R., Hoetelmans, R. M. W., Mathôt, R. A. A., van Gorp, E. C. M., Meenhorst, P. L., Mulder, J. W., & Beijnen, J. H. (2001) · AIDS · doi:10.1097/00002030-200102160-00019 · Cited by 177
Venkatakrishnan, K., Greenblatt, D. J., Moltke, L. L., Schmider, J., Harmatz, J. S., & Shader, R. I. (1998) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1998.tb04399.x · Cited by 175
Safety of St John's wort (Hypericum perforatum)
De Smet, P. A., & Touw, D. J. (2000) · The Lancet · doi:10.1016/s0140-6736(05)73225-6 · Cited by 174
Johne, A., Schmider, J., Brockmöller, J., Stadelmann, A. M., Störmer, E., Bauer, S., Scholler, G., Langheinrich, M., & Roots, I. (2002) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200202000-00008 · Cited by 172
Maurer, G. (1985) · PubMed · Cited by 172
Kudoh, S., Fujiwara, Y., Takada, Y., Yamamoto, H., Kinoshita, A., Ariyoshi, Y., Furuse, K., & Fukuoka, M. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.3.1068 · Cited by 169
Mai, I., Stormer, E., Bauer, S., Kruger, H., Budde, K., & Roots, I. (2003) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfg002 · Cited by 169
Saint John's wort: An in vitro analysis of P‐glycoprotein induction due to extended exposure
Perloff, M. D., Von Moltke, L. L., Störmer, E., Shader, R. I., & Greenblatt, D. J. (2001) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704399 · Cited by 166
Drug interaction of St John's wort with ciclosporin
Breidenbach, T., Hoffmann, M., Becker, T., Schlitt, H., & Klempnauer, J. (2000) · The Lancet · doi:10.1016/s0140-6736(05)73359-6 · Cited by 164
Jurima-Romet, M., Crawford, K., Cyr, T., & Inaba, T. (1994) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)08427-2 · Cited by 163
P‐glycoprotein‐mediated intestinal and biliary digoxin transport in humans
Drescher, S., Glaeser, H., Mürdter, T., Hitzl, M., Eichelbaum, M., & Fromm, M. F. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2003.27 · Cited by 158
Unwanted pregnancy on self‐medication with St John's wort despite hormonal contraception
Schwarz, U. I., Büschel, B., & Kirch, W. (2003) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.01716.x · Cited by 148
Chiba, M., Hensleigh, M., Nishime, J. A., Balani, S. K., & Lin, J. H. (1996) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)07348-9 · Cited by 146
Carbamazepine is not a substrate for P‐glycoprotein
Owen, A., Pirmohamed, M., Tettey, J. N. A., Morgan, P., Chadwick, D. W., & Park, B. K. (2001) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2001.01359.x · Cited by 146
Wilkinson, G. R. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(97)00040-9 · Cited by 145
Karliova, M., Treichel, U., Malagó, M., Frilling, A., Gerken, G., & Broelsch, C. E. (2000) · Journal of Hepatology · doi:10.1016/s0168-8278(00)80321-9 · Cited by 143
Markowitz, J. S., DeVane, C. L., Boulton, D. W., Carson, S. W., Nahas, Z. H., & Risch, S. C. (2000) · Life Sciences · doi:10.1016/s0024-3205(99)00659-1 · Cited by 143
Influence of Dietary Components on the Gastrointestinal Metabolism and Transport of Drugs
Evans, A. M. (2000) · Therapeutic Drug Monitoring · doi:10.1097/00007691-200002000-00028 · Cited by 138
Clinical Guidelines for the Treatment of Depressive Disorders VII. Comorbidity
Enns, M. W., Swenson, J. R., McIntyre, R. S., Swinson, R. P., Kennedy, S. H., & The CANMAT Depression Work Group (2001) · The Canadian Journal of Psychiatry · doi:10.1177/070674372001460101007 · Cited by 136
Breidenbach, T., Kliem, V., Burg, M., Radermacher, J., Hoffmann, M. W., & Klempnauer, J. (2000) · Transplantation · doi:10.1097/00007890-200005270-00052 · Cited by 135
Characterization of human liver cytochromes P-450 involved in theophylline metabolism.
Sarkar, M. A., Hunt, C. M., Guzelian, P. S., & Karnes, H. T. (1992) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)08515-0 · Cited by 135
Moody, D. E., Alburges, M. E., Parker, R., Collins, J. M., & Strong, J. M. (1997) · PubMed · Cited by 131
Mai, I., Krüger, H., Budde, K., Johne, A., Brockmöller, J., Neumayer, H.-H., & Roots, I. (2000) · International Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cpp38500 · Cited by 127
Gastrointestinal toxicity or irinotecan.
Hecht, J. R. (1998) · PubMed · Cited by 126
Distribution of Cyclosporin in Organ Transplant Recipients
Akhlaghi, F., & Trull, A. K. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241090-00001 · Cited by 126
Hyperforin, Possibly the Major Non-Nitrogenous Secondary Metabolite of Hypericum perforatum L.
Erdelmeier, C. A. J. (1998) · Pharmacopsychiatry · doi:10.1055/s-2007-979339 · Cited by 121
Mechanisms of action of loperamide.
Ooms, L. A. A., Degryse, A. ‐., & Janssen, P. A. J. (1984) · PubMed · Cited by 121
Autoinduction and steady‐state pharmacokinetics of carbamazepine and its major metabolites.
Tb, K., La, S., Rozova, G. I., & Gorkov, V. A. (1992) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1992.tb04089.x · Cited by 120
Lack of effect of St John's Wort on carbamazepine pharmacokinetics in healthy volunteers
Burstein, A. (2000) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2000.111530 · Cited by 118
Butterweck, V., Böckers, T. M., Korte, B., Wittkowski, W., & Winterhoff, H. (2002) · Brain Research · doi:10.1016/s0006-8993(01)03394-7 · Cited by 117
Markham, A., & Wagstaff, A. J. (1998) · Drugs · doi:10.2165/00003495-199855020-00012 · Cited by 116
HERBAL SUPPLEMENTS: A POTENTIAL FOR DRUG INTERACTIONS IN TRANSPLANT RECIPIENTS
Barone, G. W., Gurley, B. J., Ketel, B. L., & Abul‐Ezz, S. R. (2001) · Transplantation · doi:10.1097/00007890-200101270-00012 · Cited by 115
Metabolism of Amprenavir in Liver Microsomes: Role of CYP3A4 Inhibition for Drug Interactions
Decker, C. J., Laitinen, L. M., Bridson, G. W., Raybuck, S. A., Tung, R. D., & Chaturvedi, P. R. (1998) · Journal of Pharmaceutical Sciences · doi:10.1021/js980029p · Cited by 114
Canal, P., Gay, C., Dezeuze, A., Douillard, J., Bugat, R., Brunet, R., Adenis, A., Herait, P., Lokiec, F. M., & Mathieu-Boué, A. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.10.2688 · Cited by 108
Bleiberg, H., & Cvitkovic, E. (1996) · European Journal of Cancer · doi:10.1016/0959-8049(96)00293-6 · Cited by 105
SSRIs and St.John's Wort: possible toxicity?
Gordon, J. B. (1998) · PubMed · Cited by 103
Effects of Grapefruit Juice and Orange Juice on the Intestinal Efflux of P-Glycoprotein Substrates
Tian, R., Koyabu, N., Takanaga, H., Matsuo, H., Ohtani, H., & Sawada, Y. (2002) · Pharmaceutical Research · doi:10.1023/a:1016100715125 · Cited by 103
Venkatakrishnan, K., Moltke, L. L., & Greenblatt, D. J. (1999) · The Journal of Clinical Pharmacology · doi:10.1177/00912709922008173 · Cited by 102
Barbenel, D., Yusufi, B., O'Shea, D. B., & Bench, C. J. (2000) · Journal of Psychopharmacology · doi:10.1177/026988110001400113 · Cited by 88
Staffeldt, B., Kerb, R., Brockmöller, J., Ploch, M., & Roots, I. (1994) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/089198879400700113 · Cited by 87
Methadone Maintenance Treatment and St. John’s Wort: A Case Report
Eich-Höchli, D., Oppliger, R., Golay, K. P., Baumann, P., & Eap, C. B. (2003) · Pharmacopsychiatry · doi:10.1055/s-2003-38090 · Cited by 81
Current perspectives on oral contraceptive use
Burkman, R. T., Collins, J. A., SHULMAN, L. P., & Williams, J. (2001) · American Journal of Obstetrics and Gynecology · doi:10.1067/mob.2001.117416 · Cited by 80
Rao, U. S. M., & Scarborough, G. A. (1994) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)10165-x · Cited by 78
Tacrolimus-induced nephrotoxicity unmasked by induction of the CYP3A4 system with ST JOHN???S wort
Bolley, R., lke, C. Z., Kammerl, M., Fischereder, M., & Kr�mer, B. K. (2002) · Transplantation · doi:10.1097/00007890-200203270-00035 · Cited by 72
Fugh‐Berman, A. (1999) · Archives of Internal Medicine · doi:10.1001/archinte.159.16.1957 · Cited by 71
Consumer Use of St. John's Wort: A Survey on Effectiveness, Safety, and Tolerability
Beckman, S. E., Sommi, R. W., & Switzer, J. (2000) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.20.6.568.35152 · Cited by 71
Spinella, M., & Eaton, L. A. (2002) · Brain Injury · doi:10.1080/02699050110103319 · Cited by 70
Possible serotonin syndrome after combination of buspirone and St John's Wort
Dannawi, M. (2002) · Journal of Psychopharmacology · doi:10.1177/026988110201600420 · Cited by 69
Relative Contribution of CYP3A to Amitriptyline Clearance in Humans: In Vitro and In Vivo Studies
Venkatakrishnan, K., Schmider, J., Harmatz, J. S., Ehrenberg, B. L., Moltke, L. L., Graf, J. A., Mertzanis, P., Corbett, K. E., Rodriguez, M. C., Shader, R. I., et al. (2001) · The Journal of Clinical Pharmacology · doi:10.1177/00912700122012634 · Cited by 63
St. John's Wort Extract Induces CYP3A and CYP2E1 in the Swiss Webster Mouse
Bray, B. J. (2002) · Toxicological Sciences · doi:10.1093/toxsci/66.1.27 · Cited by 62
Lacarelle, B., Rahmani, R., de Sousa, G., Durand, A., Placidi, M., & Cano, J. P. (1991) · Fundamental and Clinical Pharmacology · doi:10.1111/j.1472-8206.1991.tb00746.x · Cited by 61
Pelkonen, O., Myllynen, P. K., Taavitsainen, P., Boobis, A. R., Watts, P. S., Lake, B. G., Price, R. J., Renwick, A. B., Gómez‐Lechón, M. J., Castell, J. V., et al. (2001) · Xenobiotica · doi:10.1080/00498250110055479 · Cited by 61
Staffeldt, B., Kerb, R., Brockmöller, J., et al. (1994) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/089198879400701s13 · Cited by 60
Hypericum perforatum (St John's wort) in depression: pest or blessing?
Rey, J. M., & Walter, G. (1998) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.1998.tb123424.x · Cited by 59
Side-effects of Antidepressants
Cookson, J. (1993) · British Journal of Psychiatry · doi:10.1192/s0007125000292325 · Cited by 56
Schulz, V. (2002) · Phytomedicine · doi:10.1078/09447110260571742 · Cited by 54
Carbamazepine induces multiple cytochrome P450 subfamilies in rats
Tateishi, T., Asoh, M., Nakura, H., Watanabe, M., Tanaka, M., Kumai, T., & Kobayashi, S. (1999) · Chemico-Biological Interactions · doi:10.1016/s0009-2797(98)00110-0 · Cited by 53
In vitro inhibition of simvastatin metabolism in rat and human liver by naringenin
Ubeaud-Séquier, G., Hagenbach, J., Vandenschrieck, S., Jung, L., & Koffel, J.-C. (1999) · Life Sciences · doi:10.1016/s0024-3205(99)00380-x · Cited by 43
Herbal Medicines as a Factor in Delirium
Khawaja, I. S., Marotta, R. F., & Lippmann, S. (1999) · Psychiatric Services · doi:10.1176/ps.50.7.969a · Cited by 43
Oral Contraceptives: An Update on Health Benefits and Risks
Borgelt, L. M. (2001) · Journal of the American Pharmaceutical Association (1996) · doi:10.1016/s1086-5802(16)31329-8 · Cited by 40
Agrosí, M., Mischiatti, S., Harrasser, P. C., & Savio, D. (2000) · Phytomedicine · doi:10.1016/s0944-7113(00)80029-x · Cited by 39
Interactions between clinically used drugs and oral contraceptives.
Bolt, H. M. (1994) · Environmental Health Perspectives · doi:10.1289/ehp.94102s935 · Cited by 30
Methadone therapy for opioid dependence.
Krambeer, L. L., McKnelly, W., Gabrielli, W. F., & Penick, E. C. (2001) · PubMed · Cited by 29
ST. JOHN'S WORT AND ORAL CONTRACEPTIVES: REASONS FOR CONCERN?
Murphy, P. A. (2002) · Journal of Midwifery & Women s Health · doi:10.1016/s1526-9523(02)00321-5 · Cited by 28
Toxic delirium possibly caused by loperamide
Schwartz, R. H., & Rodriguez, W. J. (1991) · The Journal of Pediatrics · doi:10.1016/s0022-3476(05)83407-9 · Cited by 21
Cited by
Herb-Drug Interactions: A Literature Review
Hu, Z., Yang, X., Ho, P. C. L., Chan, S. Y., Heng, P. W. S., Chan, E., Duan, W., Koh, H. L., & Zhou, S. (2005) · Drugs · doi:10.2165/00003495-200565090-00005 · Cited by 633
Self-citationStructure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition
Zhou, S.-F. (2008) · Xenobiotica · doi:10.1080/00498250701867889 · Cited by 599
Self-citationInhibition and induction of human cytochrome P450 enzymes: current status
Pelkonen, O., Turpeinen, M., Hakkola, J., Honkakoski, P., Hukkanen, J., & Raunio, H. (2008) · Archives of Toxicology · doi:10.1007/s00204-008-0332-8 · Cited by 569
The Role of Transporters in the Pharmacokinetics of Orally Administered Drugs
Shugarts, S., & Benet, L. Z. (2009) · Pharmaceutical Research · doi:10.1007/s11095-009-9924-0 · Cited by 438
The mechanisms of pharmacokinetic food-drug interactions – A perspective from the UNGAP group
Koziolek, M., Alcaro, S., Augustijns, P., Basit, A. W., Grimm, M., Hens, B., Hoad, C. L., Jedamzik, P., Madla, C. M., Maliepaard, M., et al. (2019) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2019.04.003 · Cited by 385
Metadata
- Authors
- Zhou, S., Chan, E., Pan, S.-Q., Huang, M., & Lee, E. J. D.
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2004-06
- Volume
- 18
- Issue
- 2
- Pages
- 262-276
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- OpenAlex
- W2170492741
- Cited by
- 253
- References
- 137
- FWCI
- 42.14
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.